Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business licensing deal

Dr Reddy's Gilead yearly lenacapavir license

Analysis based on 7 articles · First reported Sep 17, 2026 · Last updated Sep 17, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The deal is a modest positive for Abbott Laboratories, expanding its public-health access portfolio and long-acting HIV pipeline without upfront royalty costs, though revenue impact depends on eventual regulatory approval of once-yearly lenacapavir. For Gilead Sciences it broadens low- and lower-middle-income market access and manufacturing capacity for lenacapavir, a strategic franchise, with limited near-term earnings effect since the annual formulation remains investigational.

pharmaceuticals healthcare biotechnology

Abbott Laboratories announced on September 17, 2026 a royalty-free, non-exclusive voluntary licensing agreement with Gilead Sciences covering investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreement is intended to support manufacturing readiness, technology transfer and future supply planning across 120 high-incidence licensed countries, including India, primarily low- and lower-middle-income nations. It builds on the October 2024 voluntary licence between the two companies covering twice-yearly lenacapavir for HIV prevention and treatment. Once-yearly lenacapavir is still being evaluated in Gilead Sciences' Phase 3 PURPOSE 365 study and has not been approved by any regulatory authority; its safety and efficacy for annual HIV prevention have not been established. The twice-yearly formulation is already approved in multiple countries for treatment of adults with multidrug-resistant HIV and for HIV prevention, and is recommended by the World Health Organization; it has been approved for prevention by the United States — Food and Drug Administration and the European Union — European Medicines Agency. Alongside Abbott Laboratories, Gilead Sciences signed five other voluntary licensing agreements with partners manufacturing twice-yearly lenacapavir, including Emcure Pharmaceuticals, Eva Pharma, Abbott Laboratories, Hetero Drugs and Mylan. In India, Abbott Laboratories and other companies in the broader licensing agreement secured a waiver for local clinical trials, and the subject expert committee reviewing the drug granted a favorable recommendation, with final marketing approval still pending from the India — Central Drugs Standard Control Organisation. Deepak Sapra, CEO of API and Services at Abbott Laboratories, said the deal reflects continued commitment to global HIV prevention efforts and could offer an additional long-acting prevention option where access and adherence remain challenges.

95 Abbott Laboratories signed licensing agreement Gilead Sciences
60 Gilead Sciences signed licensing agreements
stock
Signed the royalty-free non-exclusive voluntary licence for once-yearly lenacapavir, expanding its HIV prevention portfolio and public-health access franchise across 120 licensed countries.
Importance 95.0 Sentiment 25.0
stock
Granted the voluntary licence and signed five other licensing agreements, broadening manufacturing and supply capacity for its lenacapavir franchise in low- and lower-middle-income markets.
Importance 90.0 Sentiment 15.0
cnt
Included among the 120 high-incidence licensed territories; local companies secured a clinical trial waiver and await final marketing approval from the domestic regulator.
Importance 40.0 Sentiment 5.0
govactor
Its subject expert committee recommended approval of lenacapavir in India, but final marketing approval for the drug is still pending.
Importance 25.0 Sentiment 0.0
ngo
Recommends twice-yearly lenacapavir in its HIV prevention guidelines, supporting the broader access rationale behind the licensing agreement.
Importance 20.0 Sentiment 0.0
per
CEO of API and Services at Abbott Laboratories who publicly commented on the agreement and its potential to broaden long-acting HIV prevention access.
Importance 20.0 Sentiment 0.0
govactor
Has approved twice-yearly lenacapavir for HIV prevention, while the once-yearly formulation covered by the new licence remains unapproved.
Importance 15.0 Sentiment 0.0
govactor
Has approved twice-yearly lenacapavir for HIV prevention, while the once-yearly formulation covered by the new licence remains unapproved.
Importance 15.0 Sentiment 0.0
priv
One of five other partners that signed voluntary licensing agreements with Gilead Sciences for twice-yearly lenacapavir.
Importance 10.0 Sentiment 5.0
priv
One of five other partners that signed voluntary licensing agreements with Gilead Sciences for twice-yearly lenacapavir.
Importance 10.0 Sentiment 5.0
priv
One of five other partners that signed voluntary licensing agreements with Gilead Sciences for twice-yearly lenacapavir.
Importance 10.0 Sentiment 5.0
stock
One of five other partners that signed voluntary licensing agreements with Gilead Sciences for twice-yearly lenacapavir.
Importance 10.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.